User profiles for Michael E. Abram
 | Michael E. AbramSenior Director, Translational Medicine, HilleVax Verified email at hillevax.com Cited by 4184 |
Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication
ME Abram, AL Ferris, W Shao, WG Alvord… - Journal of …, 2010 - Am Soc Microbiol
There is considerable HIV-1 variation in patients. The extent of the variation is due to the
high rate of viral replication, the high viral load, and the errors made during viral replication. …
high rate of viral replication, the high viral load, and the errors made during viral replication. …
[HTML][HTML] Nirsevimab for prevention of RSV in healthy late-preterm and term infants
…, VS Mankad, P Ren, T Takas, ME Abram… - … England Journal of …, 2022 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …
infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
…, PM McTamney, RH Arends, ME Abram… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Nirsevimab is an extended half-life monoclonal antibody specific for the prefusion conformation
of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and …
of the respiratory syncytial virus (RSV) F protein, which has been studied in preterm and …
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
ME Abram, RM Hluhanich, DD Goodman… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Elvitegravir (EVG) is an effective HIV-1 integrase (IN) strand transfer inhibitor (INSTI) in
advanced clinical development. Primary INSTI resistance-associated mutations (RAMs) at six IN …
advanced clinical development. Primary INSTI resistance-associated mutations (RAMs) at six IN …
Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a …
…, JM Custodio, ME Abram… - JAIDS Journal of …, 2016 - journals.lww.com
Background: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal
and bone safety compared with TDF-containing regimens. We report the 48 week safety and …
and bone safety compared with TDF-containing regimens. We report the 48 week safety and …
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment …
…, D Ward, J Morales-Ramirez, M Yan, ME Abram… - The lancet HIV, 2016 - thelancet.com
Background Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside
reverse transcriptase inhibitor (NRTI) backbone. However, tenofovir disoproxil fumarate is …
reverse transcriptase inhibitor (NRTI) backbone. However, tenofovir disoproxil fumarate is …
Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences
Background More than 2 million SARS-CoV-2 genome sequences have been generated and
shared since the start of the COVID-19 pandemic and constitute a vital information source …
shared since the start of the COVID-19 pandemic and constitute a vital information source …
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication
The genetic variation in HIV-1 in patients is due to the high rate of viral replication, the high
viral load, and the errors made during viral replication. Some of the mutations in reverse …
viral load, and the errors made during viral replication. Some of the mutations in reverse …
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study …
Background Nirsevimab is an extended half-life monoclonal antibody to the respiratory
syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV …
syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV …
